GlassScriptPhysician profile
Anjali Singla
NPI 1508157629
$1,921.74
in general payments reported to CMS, 2019-2025
16 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.84 · 2020: $20.98 · 2021: $14.95 · 2022: $59.67 · 2023: $286 · 2024: $737 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785 · Education: $27.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.24 |
| Education | $27.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $359.11 | 2022-2025 | Krystexxa, Tavneos, Parsabiv |
| Calliditas Therapeutics US INC. | $217.00 | 2024-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.58 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $158.52 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $158.04 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $157.82 | 2023-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $133.97 | 2023-2025 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $122.47 | 2023-2025 | |
| Travere Therapeutics, INC. | $105.09 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $91.23 | 2024-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $81.36 | 2020-2024 | Veltassa |
| Novo Nordisk INC | $60.85 | 2023-2024 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $25.69 | 2022 | |
| Horizon Therapeutics Plc | $24.97 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $14.95 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.09 | 2024 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.